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Abstract
The mechanistic details of most disease-causing mutations remain poorly explored within the context of regulatory
networks. We present a high-resolution three-dimensional integrated regulatory network (iRegNet3D) in the form of
a web tool, where we resolve the interfaces of all known transcription factor (TF)-TF, TF-DNA and chromatin-
chromatin interactions for the analysis of both coding and non-coding disease-associated mutations to obtain
mechanistic insights into their functional impact. Using iRegNet3D, we find that disease-associated mutations may
perturb the regulatory network through diverse mechanisms including chromatin looping. iRegNet3D promises to
be an indispensable tool in large-scale sequencing and disease association studies.
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Background
Genetic factors underlie many human diseases [1] and
are being identified at an ever-increasing rate through
both targeted and genome-scale sequencing studies. For
example, genome-wide association studies (GWASs) have
identified more than 20,000 robust genotype-phenotype as-
sociations [2, 3]. Recent technological advances, including
next-generation sequencing (NGS)-based approaches, have
given rise to the discovery of a plethora of disease-
associated genes and mutations [4, 5]. Yet little of this
abundance of information has been translated into drug de-
velopment and therapeutic applications, although disease-
associated genes and mutations are being identified at an
increasingly high rate. Indeed, most US Food and Drug Ad-
ministration (FDA)-approved drugs are palliative, aimed
merely at relieving symptoms, and have been developed
without recourse to knowledge of the underlying molecular
mechanisms of disease [6]. This lack of target specifi-
city is largely attributable to our lack of knowledge of
the pathogenic mechanisms underlying most of these
disease-associated genes and their mutations. There is
thus an urgent need for systematic studies that provide
insight into the mechanisms by which such mutations
cause disease.
Previous studies have indicated that in-frame disease-
associated coding mutations commonly alter protein-
protein and protein-DNA interactions [7, 8], and that
they preferentially perturb strong and stable biophysical
interactions involved in key cellular processes [9]. Non-
coding disease mutations have been reported to be
enriched in DNase I hypersensitive sites and transcription
factor binding motifs [10], and they have been shown to
cause disease by disrupting transcriptional activation,
trans-regulatory RNAs, splicing and translational regu-
lation [11]. For instance, mutations in cis-regulatory
elements have been found to exert a profound effect
on carcinogenesis via differential transcription factor (TF)
recruitment, altered binding kinetics or altered enhancer-
promoter interactions [12]. Increasing evidence from
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chromatin conformation capture (3C)-based approaches,
such as Hi-C [13], suggests that eukaryotic chromosomes
are organized into higher order structures such as topo-
logically associating domains (TADs) that are specified by
DNA-binding proteins. These domains are vital for proper
transcriptional regulation [14]; for example, their disrup-
tion has been implicated in oncogenic activation in gli-
omas [15]. Therefore, DNA-binding proteins including
TFs can play multiple and complex roles in ensuring ap-
propriate transcriptional regulation, and alterations of TF
interactions through either coding or non-coding muta-
tions can help to explain disease mechanisms [16]. Re-
cently, pioneering high-throughput experiments have
demonstrated how coding TF mutations affect TF-DNA
interactions [17], further supporting the need for inte-
grated analyses of both the protein and DNA components
of transcriptional regulatory networks. Here, we construct
the first three-dimensional integrated regulatory net-
work (iRegNet3D) that combines TF-TF, TF-DNA and
chromatin-chromatin interactions and TAD informa-
tion to improve our understanding of the underlying
pathogenic mechanisms of both coding and non-coding
regulatory mutations. Based on the proteome-scale
homology model approach we developed previously [7, 18,
19] and the Hi-C datasets, we have attempted to resolve
the binding interfaces for all three types of interaction at
high resolution in iRegNet3D. Furthermore, we have inte-
grated the information of 50,877 coding and non-coding
mutations into our database. We have built iRegNet3D as
a web tool that allows users to query TFs or a list of muta-
tions and see how the mutations affect network structure.
To study genetic mutations that alter gene regulation
systematically, we compiled a list of disease-associated
regulatory mutations from the Human Gene Mutation
Database (HGMD) [20] including both missense coding
mutations in TFs and non-coding mutations distributed
throughout the genome. We find that disease-causing
missense mutations in TFs are enriched both in protein-
binding and DNA-binding interfaces, whereas non-
coding disease-associated mutations are enriched at
transcription start sites and enhancers. More generally,
disease-associated mutations are found more frequently
in TF binding motifs than are non-disease single nucleo-
tide polymorphisms (SNPs) in the general population.
Using Hi-C data, we show that non-coding mutation
pairs across interacting chromatin regions are more
likely to be associated with the same disease than muta-
tion pairs across non-interacting regions. By integrating
these interaction networks, we find that mutations in TF
binding motifs across interacting loci of the same TF, or
two motifs of interacting TFs, are more likely to cause
the same disease. These results establish our iRegNet3D
not only as a valuable resource to study the molecular
mechanisms of both coding and non-coding regulatory
mutations on a genomic scale, but also as an indispens-
able framework for interpreting the results of numerous




We previously compiled a list of experimentally validated
high-quality binary protein-protein interactions in our
HINT database [21]. We also collated a comprehensive list
of experimentally validated and manually curated TFs
from multiple sources [22–24]. To determine protein- and
DNA-binding interfaces on these TFs, we used a hom-
ology modelling approach [7] for all amenable TF-TF and
TF-DNA interactions in human, when co-crystal struc-
tures are not available (Fig. 1a). This resource-intensive
process entails finding the most compatible co-crystal
protein-protein and protein-DNA Protein Data Bank
(PDB) structure (the template) for a given TF-TF or TF-
DNA interaction (the targets) based on the sequence
homology between the protein targets and all available
PDB templates. We then prepared sequence alignments
between the target protein sequences and the highest
ranking template sequences. Interactions where either
protein had coverage or sequence identity <40% were not
considered amenable to modelling. We used MODELLER
[25] to perform the actual homology modelling, which
performs gap closing and insertions, and alleviates steric
clashes through side-chain rearrangements. Finally, we
evaluated models for the existence of knots, and elimi-
nated any homology model that contained them. We also
included available high-quality data on DNA-binding in-
terfaces [22]. Overall, approximately 20% of the TF-TF
and TF-DNA binding interfaces in iRegNet3D came from
experimentally solved co-crystal structures, and 80% of
the interfaces were inferred by our homology modelling
method. For chromatin interactions, a list of intra-
chromosomal chromatin interactions was obtained by
combining anchor region information with target region
information from the Hi-C data from [26]. We also inte-
grated data of TADs from [26] into iRegNet3D. To facili-
tate the use of these data, we integrated the information of
50,877 coding and non-coding inherited disease-
associated mutations [20] and built a web interface that al-
lows users to query for specific disease-associated muta-
tions as well as transcription factors. Users can visualize
TF-TF interactions through modular diagrams, obtain the
number of HGMD mutations located at each TF-TF and
TF-DNA interface grouped by associated disease and
traverse the TF-TF interaction network conveniently
(Fig. 1b). Furthermore, users can upload a list of muta-
tions, which our web tool will take as input and calcu-
late a number of summary statistics including the
number of coding mutations in TFs, the number of
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Fig. 1 Construction and user interface of iRegNet3D. a. Homology modelling in the construction of iRegNet3D. b User interface of the iRegNet3D
web tool showing the query page of the vitamin D receptor (VDR)
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non-coding mutations, the fraction of mutation pairs
across interacting TFs and the fraction of mutation
pairs across interacting chromatin regions. Batch down-
load is provided for our TF-TF interaction network, DNA-
binding domain of TFs, chromatin interaction network
and TAD boundaries. Our iRegNet3D web tool is now
available at http://iregnet3d.yulab.org.
Our iRegNet3D is different from existing tools analysing
regulatory networks. For example, iBIG [27] collected a
number of regulatory networks including pathway interac-
tions, protein-protein interactions and genetics interactions,
and claimed to be a tool for building and visualizing regula-
tory networks especially from microarray data on human
disease. However, it focuses more on building genome-wide
networks perturbed by disease rather than identifying spe-
cific interactions disrupted by disease-associated mutations.
Similar tools using gene regulatory networks include
HumanNet [28] and MORPHIN [29]; however, these tools
are aimed at discovering novel genes rather than explaining
currently known disease mutations. Other existing tools
focus on specific aspects of regulatory networks, such as
protein-protein interactions as in the case of INstruct [19]
and HINT [21] that we developed before, and gene-
phenotype relationships as in the case of Phenolyzer [30].
To our knowledge, iRegNet3D is the only tool that inte-
grates TF-TF interactions, TF-DNA interactions and
chromatin-chromatin interactions as well as TADs to study
mutation/gene-phenotype relationships and provide mech-
anistic insights of disease-associated mutations in both cod-
ing and non-coding regions.
Disease-associated missense mutations in transcription
factors are significantly enriched in interfaces that
mediate protein or DNA binding
The practical utility of iRegNet3D was first tested in in-
vestigating disease-associated missense mutations in
transcription factors. Mutations within coding regions
can be divided into in-frame mutations and frameshift
mutations. The former category can be further parti-
tioned into missense mutations and in-frame insertions
or deletions. Missense mutations may cause disease by
altering protein stability and aggregation [31], as well as
by disrupting specific protein-protein interactions or
protein-DNA interactions [32]. Coding mutations from
the HGMD database are known to cause a variety of dif-
ferent diseases, most frequently affecting metabolism,
development and the nervous system (Additional file 1).
In iRegNet3D we resolved 7671 DNA-binding interfaces
of all 1801 DNA-binding proteins, the majority of which
are TFs, for both protein-protein and protein-DNA in-
teractions at atomic resolution. Since many DNA-bind-
ing interfaces are known to simultaneously participate
in protein-protein interactions, we considered these
“double” interfaces that bind both DNA and protein as
a separate category. We collected 3143 pathogenic mis-
sense mutations from HGMD and 17,507 missense SNPs
from the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project [33] that reside
within the coding regions of transcription factors (TFs),
and categorized them on the basis of the type of inter-
action interface in which they occur. We then calculated
odds ratio values against the expected fraction of SNPs
residing on each type of interface, which were derived as
the fraction of amino acids belonging to that type of inter-
face. The odds ratio measures the enrichment of disease
mutations in a certain type of interface over random ex-
pectation. AlthoughTFs are defined by their ability to bind
DNA, we were surprised to discover that disease-
associated mutations in TFs are more enriched on
protein-protein interfaces than on protein-DNA interfaces
(odds ratio = 2.23, P < 10–3 for 718 mutations on double
binding interfaces; odds ratio = 2.71, P < 10–3 for 899
mutations on protein-binding interfaces; odds ratio = 2.52,
P < 10–3 for 1140 mutations on DNA-binding interfaces;
Fig. 2a), although all interaction interfaces exhibited sig-
nificant enrichment. By contrast, SNPs from the general
population that are not associated with deleterious effects
are depleted in interfaces that mediate protein-protein or
protein-DNA interactions (odds ratio = 0.67, P < 10–3 for
823 SNPs on double binding interfaces; odds ratio = 0.73,
P < 10–3 for 697 SNPs on protein-binding interfaces; odds
ratio = 0.79, P < 10–3 for 2222 SNPs on DNA-binding in-
terfaces; Fig. 2b). These trends still hold even if only
protein-protein and protein-DNA interactions with avail-
able co-crystal structures are employed (Additional file 2).
Further, we found that mutation pairs across interacting
TFs are much more likely (7.3% of pairs, n = 44,821) to
cause the same disease than pairs across non-interacting
TFs (0.52% of pairs, n = 8,670,342, P < 10–3; Fig. 2c). Taken
together, these results suggest that the alteration of either
protein-interacting or DNA-interacting interfaces on TFs
is a common mechanism of disease. Identifying interface
binding partners should help to establish novel disease
genes and identify specific functions disrupted by the mu-
tation leading to disease.
Interestingly, we find that two mutations across inter-
acting TFs can cause the same disease in different ways.
In our iRegNet3D analyses, we identified a total of 2036
mutation pairs on TF-TF interaction interfaces, and
3316 mutation pairs where one mutation is on the TF-
TF interaction interface and the other is on the TF-DNA
interaction interface. A pair of mutations located at the
interaction interface between the two TFs could poten-
tially disrupt or enhance their binding. For example, a
missense mutation in TP53 (c. 733G > A, G244D) and a
missense mutation (c. 5191C >A, T1691K) in BRCA1 have
both been found to cause breast cancer [34, 35]. These
two transcription factors are both involved in DNA
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damage repair, and they have been shown to interact with
each other both physically and functionally [36, 37]. Both
mutations are located at the interaction interface between
these two proteins (Fig. 2d). The Gly 244 residue on p53 is
located on its L3 loop, which has been shown to interact
with the Brca1 C-terminal (BRCT) domain of BRCA1.
Thr 1691 of BRCA1 is located at the BRCT domain be-
tween β3 and α2 [35]. Therefore, alterations to the binding
between these two proteins might constitute the mechan-
ism by which these mutations cause breast cancer.
An alternative mechanism can be demonstrated by a
missense mutation in HNF1A (c.26A > C, Q9P) and a
missense mutation in HNF1B (c.406C > G, Q136E). Both
mutations cause maturity-onset diabetes of the young
(MODY) [38, 39], and HNF1A forms heterodimers with
HNF1B through their N-terminal dimerization interfaces
[40–42]. The former mutation is located at the dimerization
interface of HNF1A and may lead to the abolition of its het-
erodimerization with HNF1B, whereas the latter mutation
is located at the DNA-binding interface of HNF1B (Fig. 2e).
The Q136E mutant protein has been shown to have no de-
tectable DNA-binding ability [43]. Because dimerization is
required for members of the HNF1 homeoprotein family of
transcription factors to bind DNA [44, 45], the alteration of
Fig. 2 Analysis of disease-causing missense mutations on transcription factors. a Odds ratio for the distribution of transcription factor HGMD missense
mutations in different interaction interfaces. ***P < 10–3. P values calculated using the Z-test on log odds ratio. Error bars indicate ± standard error (SE).
b Odds ratio for the distribution of transcription factor ESP missense SNPs in different interaction interfaces. ***P < 10–3, **P < 10–2. P values calculated
using the Z-test on log odds ratio. Error bars indicate ± SE. c Fraction of mutation pairs across two transcription factors causing the same disease.
***P < 10–3. Error bars indicate ± standard error of the mean (SEM). P values calculated using the cumulative binomial test. d Schematic diagram of a
mutation pair causing the same disease across a TF-TF interaction interface. e Schematic diagram of a mutation pair causing the same disease where
one mutation is on the TF-TF interaction interface while the other is on the TF-DNA interaction interface
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the heterodimerization between HNF1A and HNF1B and
the abolition of the DNA-binding activity of HNF1B have
essentially the same impact on transcriptional regulation;
hence both lead to MODY.
These findings have served to identify potential mecha-
nisms by which two different and non-allelic mutations
can cause the same disease. They also highlight the im-
portance of integrating different types of molecular inter-
actions as a means to fully understand the mechanisms of
pathogenic regulatory mutations. Careful examination of
such mutations within the framework of iRegNet3D
may shed new light on these mutations and the means
by which they give rise to the corresponding disor-
ders at the molecular level. These mechanistic models
will provide critical insights to design follow-up studies
and experimental validations.
Non-coding regulatory mutations across interacting
chromosomal regions tend to be associated with the
same disease
A large number of non-coding mutations have been
identified and implicated in the pathogenesis of a variety
of different diseases, including cancer [46]. Genome-
wide association studies (GWASs) and quantitative trait
loci (QTL) studies have been widely applied to the iden-
tification and annotation of non-coding mutations [47].
Previous studies have found that Mendelian disease mu-
tations and recurrent cancer somatic mutations are
enriched within promoter regions [48]. Enhancers in the
human genome are also prone to deactivating mutations
that disrupt the binding of transcription factors [49]. To
study the localization of non-coding disease-associated
mutations across the human genome, we categorized
2594 HGMD non-coding mutations using chromatin
state annotation data from ENCODE. These mutations are
most frequently associated with cancer, developmental dis-
ease and diseases of the digestive system (Additional file 1).
We observed that mutations in non-coding regions
(Additional file 3) are significantly enriched in transcrip-
tion start sites and enhancers (Fig. 3a), consistent with
their presumed role in transcriptional regulation.
Since increasing evidence has emerged for distal en-
hancers coming into close proximity with promoters via
a looping mechanism [50–53] and their interaction is
fundamental to the control of transcriptional activity
[54], we sought to explore how chromatin interactions
might be related to the phenotypic impact of non-coding
mutations using iRegNet3D. We classified each pair of
non-coding mutations as ‘in the same anchor’ (n = 3480),
‘across interacting regions’ (n = 166), ‘across non-interacting
regions of the same chromosome’ (n = 3164) or ‘on differ-
ent chromosomes’ (n = 1,128,161) using published 3D chro-
matin interactome data [26]. Consistent with the idea that
mutations in the same anchor region are likely to affect the
same regulatory element, we find these pairs to have an
80% probability of being associated with the same disease
(Fig. 3b). Notably, two mutations across interacting chro-
matin regions have a significantly higher chance of causing
the same disease than two mutations in non-interacting re-
gions of the same chromosome (P < 10–40, cumulative bino-
mial test; Fig. 3b). To eliminate the confounding influence
of proximal interacting regions that could in fact be part of
a single regulatory element, we required a minimum dis-
tance between the two mutations. We were able to obtain
the same results when we selected a threshold of 20 kb
(P < 10–13, cumulative binomial test; Fig. 3b) or even
50 kb (P < 10–16, cumulative binomial test; Fig. 3b).
To further validate our results, we used a more recent
3D map of the human genome constructed using Hi-C
[55], and investigated whether mutations that cause the
same disease tend to be located in regions that have a
high contact frequency. Indeed, higher contact numbers
were observed between regions across which mutations
cause the same disease as compared to regions across
which mutations cause different diseases, irrespective of
the resolution of the data used (Fig. 3c). These results
strongly suggest that many non-coding disease mutations
can affect the interactions between distal and proximal
regulatory elements. Indeed, instances have been reported
where single nucleotide variants either disrupt or
strengthen promoter-enhancer interactions, thereby al-
tering the transcriptional activity of the regulated gene
[56]. As an example, the single nucleotide polymorph-
ism (SNP) rs12913832 is located within a postulated
enhancer of OCA2. It has been shown using 3C that
there is a stronger interaction between the enhancer
and the OCA2 promoter for the T pigmentation-
associated allele than that observed for the
pigmentation-non-associated C allele [56].
Importantly, Hi-C studies have found that many
chromatin-chromatin interactions and topologically
associating domains are cell-type independent [57],
thereby rendering cell type matching unnecessary for
many such interactions. Nevertheless, as Hi-C data be-
come available from more cell types, our approach
would benefit from using only mutations associated
with diseases that are matched for the cell type used
for Hi-C analysis.
Analysis of non-coding disease-associated mutations that
alter TF binding motifs indicates alterations of chromatin
looping
Many types of transcriptional regulation are mediated by
transcription factors (TFs). To determine whether there
is a tendency for non-coding mutations to alter TF bind-
ing to regulatory elements, we scanned for known TF
binding motifs in genomic regions where the mutations
are located using the RTFBSDB package [58]. Perhaps
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unsurprisingly, non-coding disease mutations were found
to be enriched in TF binding motifs, whereas population
SNPs were not (Fig. 4a). In addition, as the log-likelihood
cutoff score used for identifying TF motifs increases, the
fold of enrichment becomes higher (Fig. 4a). This is sug-
gestive of an important role for alterations of TF binding
sites in the pathogenesis of human genetic disorders. We
have performed the same calculation again using only the
subset of mutations located across interacting chromatin
regions, and found that these mutations are also enriched
in TF binding sites (P = 0.017).
In addition to affecting TF-DNA binding, non-coding
mutations may also disrupt or enhance those chromatin
interactions that are mediated by TFs. Usually,
chromatin looping is facilitated by a TF multimer that
binds to distal motifs. For example, it is known that loops
mediated by CTCF dimers play a complex regulatory role
in transcription regulation [59, 60]. Additionally, multiple
TFs can form or recruit a complex to create chromatin
loops. For example, TF recruitment of RNA polymerase II
may mediate chromatin looping [61].
Since non-coding mutations may affect these TF-
mediated chromatin interactions, we focused on muta-
tions in TF binding motifs at interacting chromosomal
loci. We classified each mutation pair based on the dis-
tance and interactions between their corresponding TF
motifs. Two mutations could be located within the same
TF binding motif (‘same motif, same position’), at
Fig. 3 Analysis of disease-associated non-coding mutations and their locus heterogeneity. a Enrichment of HGMD non-coding mutations in different
gene regulatory regions. *P < 0.05, **P < 10–2, ***P < 10–3. P values calculated using the Z-test on log enrichment. Error bars indicate ± SE. b Fraction of
HGMD non-coding mutation pairs causing the same disease. Error bars indicate ± SEM. P values calculated using the cumulative binomial test.
c Normalized number of chromosomal contacts for mutation pairs associated with the same disease or different diseases. ***P < 10–3. P values
calculated using the Mann-Whitney U test. Light blue dots indicate the mean. Dark blue lines indicate the median
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Fig. 4 (See legend on next page.)
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binding motifs of the same TF at different locations
(‘same motif, different position’), at binding motifs of
two different TFs that interact physically (‘different mo-
tifs, TFs interact’) or at binding motifs of two non-
interacting TFs (‘different motifs, TFs do not interact’).
Within each group, we calculated the fraction of muta-
tion pairs causing the same disorder. Unsurprisingly,
two mutations in a single TF binding motif have a
>80% possibility of causing the same disorder (Fig. 4c–
e). In addition, mutation pairs across interacting DNA
regions located at different binding sites of the same
TF, as well as those located at binding sites of interact-
ing TFs, are all significantly more likely to be associ-
ated with the same disorder than mutation pairs
across interacting regions located at binding sites of
non-interacting TFs (Fig. 4b). This result was found to
be robust irrespective of whether the analysis was per-
formed for all mutation pairs (Fig. 4c), mutation pairs
on the same chromosome (Fig. 4d) or only mutation
pairs in the same anchor (Fig. 4e) that already have a
high baseline probability of causing the same disease.
To determine if TF-TF interactions play an important
role in mediating chromatin-chromatin interactions,
we took 4-kb windows centred at mutations in inter-
acting chromatin regions, and scanned for TF binding
motifs. Among all motif pairs across interacting chromatin
regions, we discovered that there is an enrichment of mo-
tifs of interacting TFs, and that this enrichment increases
as the matching of TF binding motifs becomes more strin-
gent (Fig. 4f). We further validated this result using an al-
ternative null model based on the fraction of interacting
TF motif pairs from a scrambled chromatin interaction
network. These results indicate that TF-mediated chroma-
tin looping may be important for understanding disease
mechanisms, and meaningful TF-TF interactions may be
encoded in the DNA sequences of regions involved in
making chromosomal contacts.
An interesting example of two mutations across inter-
acting DNA regions located within two distinct binding
sites for the same TF (Fig. 5a) is to be found on chromo-
some 11. Both of the mutations in question give rise to
congenital hyperinsulinism, characterized by dysregulated
insulin secretion and hypoglycemia, and they were
reported in two separate clinical studies [62, 63]. One of
the mutations (C to G; chr11: 17498513, hg19) is located
in the promoter region of the ABCC8 gene, 64 base pairs
upstream of the transcriptional initiation site. The other
(C to T; chr11: 17409692, hg19) is located 54 base pairs
upstream of the start codon of KCNJ11. The two muta-
tions are around 90 kb apart. Both mutations are located
within putative TFAP2A-binding motifs, and the two
chromatin loci interact. ABCC8 and KCNJ11 contribute
subunits to the β-cell ATP-sensitive K+ channel (KATP),
whose activity is dependent upon the ATP/ADP ratio and
serves to regulate insulin secretion [63]. A number of cod-
ing mutations as well as intronic mutations in the two
genes have also been reported to cause congenital hyper-
insulinism [64]. In addition, TFAP2A belongs to the AP-2
family of transcription factors that has been reported to
bind to estrogen receptor alpha to facilitate long-range
chromatin interaction and transcription [65]. Further, a
previous study has shown that TFAP2A overexpression
can lead to increased insulin receptor expression [66],
possibly disrupting insulin metabolism. It is therefore
likely that ABCC8 and KCNJ11 are co-regulated as a
result of TFAP2A-mediated chromatin looping, and
that the disruption of TFAP2A binding at either locus
leads to congenital hyperinsulinism.
Mutations across interacting DNA regions causing the
same disease have also been found to be located within
binding sites of interacting TFs (Fig. 5b). Two mutations
on chromosome 19 have been reported to be associated
with susceptibility to lung cancer. One of them (T to C;
chr19: 45927610, hg19) is located in the promoter of the
ERCC1 gene about 1 kb upstream of the start codon,
and has been reported to affect transcriptional regulation
of ERCC1 [67]. The other (G to A; chr19: 45909934, hg19)
is located 21 base pairs upstream of the start codon of the
CD3EAP gene, and the mutant allele has increased pro-
moter activity and is associated with increased expression
of CD3EAP [68]. The former mutation is within a putative
TFAP2C-binding site, whereas the latter is located within
a putative NR1I2-binding site. The two chromatin loci
(~18 kb away) interact according to Hi-C data, whilst the
protein-protein interaction between TFAP2C and NR1I2
has been reported previously [69]. As the limiting factor in
(See figure on previous page.)
Fig. 4 Analysis of disease-associated non-coding mutations located at TF binding motifs. a Enrichment of HGMD non-coding mutations and
population SNPs in TF binding motifs. *P < 0.05, **P < 10–2, ***P < 10–3. P values calculated using the Z-test on log enrichment. Error bars indicate ± SE.
b Fraction of TF binding motif-localized non-coding mutation pairs causing the same disease. Error bars indicate ± SEM. *P < 0.05. P values calculated
using the cumulative binomial test. n.s. not significant. c Fraction of TF binding motif-localized non-coding mutation pairs on the same chromosome
causing the same disease. Error bars indicate ± SEM. *P < 0.05, ***P < 10–3. P values calculated using the cumulative binomial test. d Fraction of
TF binding motif-localized non-coding mutation pairs in the same anchor causing the same disease. Error bars indicate ± SEM. **P < 10–2, ***P
< 10–3. n.s. not significant. P values calculated using the cumulative binomial test. e Fraction of TF binding motif-localized non-coding muta-
tion pairs across interacting regions causing the same disease. Error bars indicate ± SEM. ***P < 10–3. n.s. not significant. P values calculated
using the cumulative binomial test. f Enrichment of motif pairs of interacting TFs across interacting chromatin regions. Error bars indicate ± SEM.
***P < 10–3. P values calculated using the Z-test on log enrichment
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nucleotide excision repair, the expression level of ERCC1
has been shown to be associated with survival outcome in
non-small-cell lung cancer [70]. Interestingly, reduced ex-
pression of NR1I2 has also been shown to increase the risk
of lung cancer [71], consistent with an important role for
this TF in the normal expression of ERCC1. On the other
side, enhanced TFAP2C expression has been shown to
promote lung tumorigenesis and aggressiveness [72]. Con-
sidering the fact that AP-2 family TFs mediate chromatin
looping [65], it may be that the NR1I2-TFAP2C complex
facilitates chromatin looping at this locus in order to regu-
late ERCC1 and CD3EAP, and the disruption of this regu-
lation contributes to lung tumorigenesis. It is highly
interesting to perform further experiments, such as ChIP-
seq studies of TFAP2A, TFAP2C and NR1I2 in relevant
cell types, to validate these hypotheses generated by our
iRegNet3D models.
Discussion
Although, with the advent of high-throughput sequencing,
many disease-associated mutations have been identified,
there have been very few analyses that capture both coding
and non-coding mutations in a single genome-wide frame-
work. Here, we constructed an integrated regulatory
network, iRegNet3D, that encompasses TF-TF, TF-DNA
and chromatin interactions as well as topologically associ-
ating domains (TADs). iRegNet3D provides a user-
friendly web interface that allows users to query TFs and
disease-associated mutations to examine how the regula-
tory network structure is perturbed. Using a high-quality
list of disease mutations, we have traced pathogenic
mechanisms to the interface of protein- and DNA-
interaction networks. Specifically, we find significant
enrichment of missense mutations in both protein-
binding and DNA-binding interfaces of TFs, as well as
in the TF binding sites at transcription start sites and en-
hancers. Similarly, mutations across the same interface of
a chromatin loop are more likely to be associated with the
same phenotypic effect than mutations in non-interacting
chromatin regions. In line with previous findings, our data
reinforce chromatin looping as an informative regulatory
paradigm that is likely to be disrupted by many pathogenic
non-coding mutations.
Importantly, the models we proposed in cases where
mutation pairs are located at binding motifs of interact-
ing TFs are not the only possibilities. One alternative
scenario is that nearby factors facilitate chromatin loop-
ing, instead of the specific TF binding sites we propose
Fig. 5 Mutations across interacting chromatin regions cause diseases by potentially disrupting TF-mediated chromatin looping. a Schematic
diagram of two mutations across interacting TF regions located at the same type of TF binding motif, and causing the same disease. b Schematic
diagram of two mutations across interacting TF regions located at two binding motifs of TFs that interact with each other, causing the same disease
Liang et al. Genome Biology  (2017) 18:10 Page 10 of 16
here. This would instead suggest that the disease muta-
tion pairs cause similar defects in transactivation but not
chromatin contacts. Hi-C data from mutant cell lines
would be required to discern if the mutations have a dis-
ruptive effect on chromatin interactions. RNA-seq or
qPCR of nearby target genes would serve to confirm ab-
errant transcriptional regulation, whilst ChIP-seq data
would confirm aberrant factor binding to motifs that
may be disrupted by the mutations.
Our current analyses are primarily limited by the avail-
able number of high-quality coding and non-coding mu-
tations for which we have direct clinical or functional
evidence for their association with specific human disor-
ders. As sequencing continues to become cheaper, add-
itional disease mutations can be incorporated into our
analysis framework and should help to generate new
insights into the transcription regulatory network
architecture. A more comprehensive protein-protein,
protein-DNA and DNA-DNA interaction network would
also increase the coverage and depth of our study.
Intriguingly, we have observed that many non-
interacting TF pairs that cause the same disease are
linked in another way: one TF binds the enhancer or
promoter of the other. We have attempted to perform
a systematic analysis to explore whether missense muta-
tions in TFs and non-coding mutations at their binding
sites tend to cause the same disease. Unfortunately, there
are currently insufficient mutation data to draw any statis-
tically meaningful conclusions. However, with the rapidly
increasing number of disease mutations and chromatin
interaction maps being reported, we plan to perform these
analyses in the near future.
Overall, our iRegNet3D framework provides new in-
sights into the mechanisms by which coding and non-
coding regulatory mutations disrupt network structure
and cause various diseases at the molecular level. This is
of great importance for the design of experimental
follow-up studies to further our understanding of these
disease genes and their mutations. With the rapidly de-
veloping genome editing technologies such as CRISPR
[73, 74], various molecular and functional experiments
can be designed to validate the disease-causing mecha-
nisms of coding and non-coding regulatory mutations
that are predicted by iRegNet3D. Furthermore, iReg-
Net3D promises to be an indispensable tool for numer-
ous ongoing large-scale sequencing projects and
genome-wide association studies (GWASs) to link
poorly understood disease genes and mutations.
Although GWASs have been hugely successful in identi-
fying variant-trait associations, they are often underpow-
ered to pinpoint the exact causal variant. iRegNet3D can
be used to generate mechanistic hypotheses by present-
ing all known connections to other chromatin regions,
TFs, and mutations that cause the same disease. It can
be used in conjunction with existing functional scoring
tools such as Combined Annotation-Dependent Depletion
(CADD) [75], Eigen [76] and FunSeq2 [77] to identify vari-
ants that lead to the phenotype. Specifically, starting from
a list of variants found by GWASs, one can pick out the
potentially causal ones by applying a filter of the functional
scores, and use iRegNet3D to generate possible models of
disruption that could be tested at the molecular level.
Conversely, if medical genomics outpaces interactome dis-
covery, disease mutation pairs could be mined to predict
TF-TF, TF-DNA or chromatin-chromatin interactions. The
mechanistic insights provided by our iRegNet3D frame-
work have the potential to greatly increase the explanatory
power of association studies, thereby helping us to achieve
better accuracy and coverage in disease mutation discovery.
Conclusions
Here we present iRegNet3D, an integrated regulatory
network incorporating TF-TF, TF-DNA, chromatin in-
teractions and TAD information at high resolution. To
our knowledge, it is the only tool that integrates multiple
regulatory networks and human disease-associated mu-
tations for the generation of mechanistic insights into
pathogenesis. Using iRegNet3D, we have demonstrated
that disease-causing missense mutations on TFs are
enriched in protein-binding and DNA-binding inter-
faces. On the other hand, disease-associated non-coding
mutations tend to impact promoters and enhancers, and
many of them alter TF binding motifs. Most importantly,
we have found that disruption of chromatin looping
through TF-TF interactions is potentially a mechanism by
which mutation pairs can cause the same disease, and that
either homo- or heterodimeric TF-TF interactions could
be involved. iRegNet3D provides a framework and a user-
friendly web tool for understanding the mechanisms by
which both coding and non-coding mutations lead to dis-
ease, and may facilitate the future discovery of hitherto
unknown disease genes and mutations.
Methods
Homology modelling of TF-TF interaction and DNA-binding
interfaces of TFs
Potential co-crystal templates for homology modelling
were ranked by the coverage and sequence identity of
the target proteins to the template. Only interactions
where either protein has coverage or sequence identity
above 40% were considered amenable to modelling. Inter-
actions with a single viable template were modelled using
that template, and models with more than one template
were modelled with the single template with the highest
match score. The match score takes into account both se-
quence identity and coverage of each target protein to the
template: m = SeqID1*Cov1 + SeqID2*Cov2. MODELLER
[25] was used for actual modelling. Any protein domains
Liang et al. Genome Biology  (2017) 18:10 Page 11 of 16
that contained interaction residues as predicted by the
models were considered interaction interfaces.
To verify the reliability of our inferred TF-TF and
TF-DNA interfaces, we performed a threefold cross-
validation, similar to what was described in [7], on the sets
of TF-TF and TF-DNA interactions separately for which
we have co-crystal structures. We split the interactions
into three subsets where co-crystal structures in the first
two subsets were used as templates to infer TF-TF or TF-
DNA interfaces in the third subset. We repeated the pro-
cedure three times for all three training-testing divisions.
More than 90% of all the TF-TF or TF-DNA interfaces
could be correctly predicted with our method.
Enrichment of TF missense mutations on protein-binding
and DNA-binding interfaces
Only TFs containing at least one protein-protein and one
protein-DNA interface were included in order to
minimize misclassifications due to incomplete TF annota-
tions. Inherited disease-causing coding mutations were
obtained from HGMD’s curated ’DM’ category. Missense
SNPs were taken from the Exome Sequencing Project if
their allele frequency was greater than 1%. We reproduced
our missense SNP results at multiple allele frequency
thresholds or using data from the 1000 Genomes Project
(data not shown). Protein interaction interfaces were col-
lected from our 3D protein interaction network (hSIN);
we also validated our results using only protein interaction
interfaces with available crystal structures (hSIN co-crystal
set; Additional file 2). For each type of interaction inter-
face, the total numbers of variants and amino acids were
counted. Finally, the fractions of amino acids and muta-
tions were computed (compared to all mutations or all
amino acids, respectively) and used to calculate odds
ratios. The formula describing the odds ratio is as follows:
OR ¼ p1= 1−p1ð Þ
p2= 1−p2ð Þ
;
where p1 is the fraction of mutations located at a type of
interface (nmut, region/nmut, total), and p2 is the fraction of
amino acid residues that belong to that type of interface













Z ¼ ln ORð Þ
SE lnOR
Enrichment of non-coding mutations on promoters and
enhancers
Non-coding disease-associated mutations were obtained
from HGMD (accessed February 2015); only mutations
within the DM, DM?, DFP and DP categories were
used for analyses. Chromatin segregation data using
ChromHMM, Segway and a combined method were
obtained from ENCODE [78] for several cell lines. For
ChromHMM annotations, Tss and TssF were regarded as
TSS segments and Enh, EnhF were regarded as enhancers.
For Segway annotations, Tss and TssF were regarded as
TSS segments and Enh, Enh1, Enh2, EnhF, EnhF1, EnhF2,
EnhF3, EnhP and EnhPr were regarded as enhancers. For
combined annotations, TSS was regarded as TSS segments
and E was regarded as enhancers. TSS regions in different
cell lines were combined, and enhancers in different cell
lines were combined. Enrichment was calculated as (nmut,
region * ltotal)/(nmut, total * lregion), where nmut, region is the
number of mutations in that type of chromatin segment,
nmut, total is the total number of mutations, lregion is the total
length of that type of segment in all the chromosomes and
ltotal is the total length of all chromosomes. Z scores for en-
















Statistical analysis of mutation pairs and their
phenotypes: coding mutations
We used the previously constructed high-quality interac-
tome INstruct [19] to determine if two proteins interact.
For mutation pairs across two different TFs, we deter-
mined if a mutation pair was ‘across interacting TFs’ or
‘across non-interacting TFs’ by checking whether the
two TFs at which the mutations are localized interact
with each other in hSIN. We then calculated the fraction
of mutation pairs causing the same disease in these two
categories. The statistical significance between the two
categories was calculated using the cumulative binomial
test.
TF binding motif mapping
Common SNPs were obtained from the UCSC Genome
Annotation database and partitioned by allele frequency.
From each category, 2000 SNPs were randomly selected.
The RTFBSDB R package [58] was used to search for TF
binding motifs within which the HGMD non-coding
mutations and common SNPs were located. Log-
likelihood score thresholds of 6, 7, 8 and 9 were used to
identify TF binding motifs.
Enrichment of non-coding mutations in TF binding motifs
Regions of 4000 bp (search regions) centred at non-coding
mutations, as well as population SNPs selected, were used
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for TF binding motif scanning. For a given mapping
threshold (6, 7, 8 or 9), enrichment of non-coding muta-
tions and population SNPs were calculated as (nvar, motif *
lmotifs in search region) / (nvar, total * lsearch region), where nvar,
motif is the number of mutations or variants in at least one
TF binding motif, nvar, total is the total number of muta-
tions or variants, lmotifs in search region is the total length of
TF binding motifs within search regions for that type of
mutation or variant and lsearch region is the total length of
all the search regions for that type of mutation or variant.
Standard errors and Z scores were calculated similarly to
the calculation above. We performed this for all four types
of mutation or variant: HGMD non-coding mutations,
population SNPs with minor allele frequencies less than
0.01, population SNPs with minor allele frequencies be-
tween 0.01 and 0.1 and population SNPs with minor allele
frequencies greater than 0.1.
Statistical analysis of mutation pairs and their
phenotypes: non-coding mutations
Disease names were mapped to Medical Subject Head-
ings (MeSH) Unique IDs or Online Mendelian Inherit-
ance in Man (OMIM) IDs using DNorm [79] (version
0.0.6). Only mutations whose associated disease names
were successfully mapped were retained; the final list
contained 1666 mutations. Chromatin interaction data
that contained a list of ‘anchors’, and a list of interactions
between chromatin regions and anchors, were obtained
from [26]. All the interactions in these files were intra-
chromosomal. Each pair of non-coding mutations was
classified as ‘in the same anchor’ if both mutations were
located at the same anchor in the anchor list, ‘in interact-
ing regions’ if one of the mutations was in an anchor
and the other was in a region interacting with that an-
chor, ‘in non-interacting regions on the same chromo-
some’ if it did not belong to the previous two categories
but was located on the same chromosome and ‘on differ-
ent chromosomes’ if the two mutations were located on
two different chromosomes. For the ‘in interacting re-
gions’ and ‘in non-interacting regions on the same
chromosome’ categories, we required that the distance
between the two mutations must be smaller than 2 Mb,
and greater than 0 kb, 2 kb or 5 kb for three different
analyses. The fractions of mutation pairs associated with
the same disease were calculated, and P values were cal-
culated using the cumulative binomial test.
For the comparison of chromatin interactions (Fig. 3c),
we obtained high-resolution Hi-C data from [55]. We
used the intra-chromosomal interaction data with resolu-
tions of 5 kb, 10 kb, 25 kb and 50 kb. We labelled muta-
tion pairs on the same chromosome as being associated
with the same disease or different diseases. For each
mutation pair, we located the corresponding chromosomal
regions and calculated the SQRTVC normalized number
of chromatin contacts by means of the raw matrix and
SQRTVC normalization vector provided in the data.
Statistical significance between the two groups was
then calculated using the Mann-Whitney U test.
For the analysis of non-coding mutations at TF binding
sites, we used the TF binding motif scanning result with a
default threshold of 6. We performed calculations for all
mutation pairs, mutation pairs on the same chromosome,
mutation pairs in the same anchor (as defined by the chro-
matin interaction data used above) and mutation pairs
across interacting regions. Mutation pairs across interacting
regions were defined using Hi-C data from [26, 80],
GSM2101551, EMBL-EBI sample E-GEOD-77266 and 5-C
data from [52]. All of these datasets contain lists of interact-
ing chromatin regions. A mutation pair was termed ‘inter-
acting’ if one of the mutations was located in a region in
the list and the other was localized to a region on the same
chromosome that interacts with the previous region. For
each calculation, only mutation pairs where both mutations
were located in at least one TF binding motif were retained.
Mutation pairs were labelled ‘same motif, same position’ if
the two mutations were located within exactly the same TF
binding site, ‘same motif, different positions’ if the two
mutations were located within the binding sites of the
same TF but at different chromosomal positions, ‘different
motifs, TFs interact’ if the two mutations were located at
the binding motifs of two TFs that interact with each
other as determined by INstruct and ‘different motifs, TFs
do not interact’ if the two mutations were located at bind-
ing motifs of two TFs that do not interact with each other.
Fractions of mutation pairs causing the same disease were
calculated, and statistical significance was calculated using
the cumulative binomial test.
Enrichment of binding motifs of interacting TFs across
interacting chromatin regions
Regions of 4000 bp centred at HGMD mutations se-
lected from mutation pairs across interacting regions
were used for TF binding motif search. The RTFBSDB R
package was used, and we employed cutoff scores of 8, 9
and 10 due to the large number of TF binding motifs
found at lower thresholds. For each pair of TF binding
motifs across interacting chromatin regions, we deter-
mined whether the corresponding TFs interact with each
other using the TF-TF interaction network of iRegNet3D.
The expected fraction of motif pairs whose corresponding
TFs interact was calculated by dividing the number of
interacting TF pairs by the number of all possible TF pairs
where both of the TFs are involved in at least one TF-TF
interaction. Enrichment of motifs of interacting TFs
was calculated against this baseline, and P values were
calculated using the Z-test on log enrichment value as
described above. The alternative null model was built by
scrambling the chromatin interaction network to produce
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motif pairs across non-interacting regions. Enrichment of
motif pairs of interacting TFs across interacting chromatin
regions was calculated against the fraction of motif pairs
of interacting TFs in this null model.
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